Radiation Therapy Alone in cT1-3N0 Non-small Cell Lung Cancer Patients Who Are Unfit for Surgical Resection or Stereotactic Radiation Therapy: Comparison of Risk-Adaptive Dose Schedules-Reference-Cited by-同舟云学术

Radiation Therapy Alone in cT1-3N0 Non-small Cell Lung Cancer Patients Who Are Unfit for Surgical Resection or Stereotactic Radiation Therapy: Comparison of Risk-Adaptive Dose Schedules

Published:2016-10-15 Issue:4 Volume:48 Page:1187-1195
ISSN:1598-2998
Container-title:Cancer Research and Treatment
language:en
Short-container-title:Cancer Res Treat

Author:

Cho Won Kyung,Noh Jae Myoung,Ahn Yong Chan,Oh Dongryul,Pyo Hongryull

Publisher

Korean Cancer Association

Subject

Cancer Research,Oncology

Link

http://e-crt.org/upload/pdf/crt-2015-391.pdf

Reference21 articles.

1. Impact of Revised Stage Classification of Lung Cancer on Survival

2. Radical radiotherapy for stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable): a systematic review

3. Excessive Toxicity When Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung Cancer

4. Fractionation and protraction for radiotherapy of prostate carcinoma

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stereotactic Body Radiation Therapy (SBRT) for Non-Small Cell Lung Cancer (NSCLC) Therapy;Cancer Research Journal;2024-06-19

2. Prospective study investigating hypofractionated proton beam therapy in patients with inoperable early stage non-small cell lung cancer;Frontiers in Oncology;2024-02-20

3. Radiotherapy in the management of lung oligometastases;Cancer/Radiothérapie;2024-02

4. An optimal dose‐fractionation for stereotactic body radiotherapy in peripherally, centrally and ultracentrally located early‐stage non‐small lung cancer;Thoracic Cancer;2023-09-10

5. Accelerated Hypofractionated Radiotherapy for Centrally Located Lung Tumours Not Suitable for Stereotactic Body Radiotherapy or Chemoradiotherapy;Clinical Oncology;2023-02